Ligand Pharmaceuticals (LGND) Revenue Growth (3y) (2013 - 2026)
Ligand Pharmaceuticals (LGND) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,200.25 Bn | 66,199.96 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.75 Bn | 466.96 Bn | 1.35 Bn | 50.07% |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 7.94% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 4.47% |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 79.44% |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 54.05% |
| 10 | Ligand Pharmaceuticals | 5.84 Bn | 5.07 Bn | 48.45 Mn | 5.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.55% |
| Dec 31, 2025 | 5.80% |
| Sep 30, 2025 | 24.93% |
| Jun 30, 2025 | -1.69% |
| Mar 31, 2025 | 7.48% |
| Dec 31, 2024 | -8.78% |
| Sep 30, 2024 | -4.61% |
| Jun 30, 2024 | -19.24% |
| Mar 31, 2024 | -12.72% |
| Dec 31, 2023 | -26.23% |
| Sep 30, 2023 | -7.74% |
| Jun 30, 2023 | -13.98% |
| Mar 31, 2023 | 9.87% |
| Dec 31, 2022 | 23.11% |
| Sep 30, 2022 | 33.65% |
| Jun 30, 2022 | 26.12% |
| Mar 31, 2022 | -5.66% |
| Dec 31, 2021 | -1.81% |
| Sep 30, 2021 | 9.34% |
| Jun 30, 2021 | -4.33% |